This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Egan, A. F.
Right arrow Articles by Kaslow, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Egan, A. F.
Right arrow Articles by Kaslow, D. C.

 Previous Article  |  Next Article 

Infection and Immunity, March 2000, p. 1418-1427, Vol. 68, No. 3
0019-9567/00/$04.00+0

Vaccine Efficacy of Recombinant Plasmodium falciparum Merozoite Surface Protein 1 in Malaria-Naive, -Exposed, and/or -Rechallenged Aotus vociferans Monkeys

Andrea F. Egan,1 Michael J. Blackman,2 and David C. Kaslow1,*

Malaria Vaccines Section and Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,1 and Division of Parasitology, National Institute for Medical Research, London, United Kingdom2

Received 22 June 1999/Returned for modification 18 August 1999/Accepted 2 November 1999

Protection against a lethal challenge infection of Plasmodium falciparum was elicited in malaria-naive Aotus vociferans monkeys by vaccination with the C terminus 19-kDa protein of the major merozoite surface protein (MSP-119) fused to tetanus toxoid universal T-cell epitopes P30 and P2. Three of four monkeys were protected against a 104-parasite challenge. Four monkeys were challenged with 105 parasites; one self-cured the infection, two were protected against high parasitemia (<2%) but were treated for severe anemia (hematocrit of <25%), and the fourth was not protected. In this model system, anemia appears to be a manifestation of incomplete protection (prolonged low-level parasitemia). Enzyme-linked immunosorbent assay (ELISA) antibody titers correlated with protection. Antibodies from some protected monkeys inhibited secondary processing of MSP-142 to MSP-133 and MSP-119. To mimic the repeated reinfections seen in regions where malaria is endemic, a second malaria parasite challenge was administered 4 months later. All P30P2MSP-119-vaccinated monkeys were protected; thus, a single challenge infection may underestimate vaccine efficacy. ELISA antibody titers correlated with protection against a second infection but had decreased compared to the first challenge. As most target populations for asexual blood-stage malaria vaccines will have been exposed to malaria parasites, a malaria parasite-exposed monkey was vaccinated with P30P2MSP-119. This monkey was completely protected, while a malaria parasite-naive P30P2MSP-119-vaccinated monkey self-cured a low-grade parasitemia. Prior malaria parasite infection primed the production of anti-native MSP-119 antibodies, which were boosted by vaccination with recombinant P30P2MSP-119. Preliminary data suggest that immunogenicity studies of vaccines designed for malaria parasite-exposed populations should also be conducted in malaria parasite-exposed subjects.

* Corresponding author. Present mailing address: Virus and Cell Biology, Merck Research Labs, WP 16-225, West Point, PA 19486. Phone: (215) 652-3929. Fax: (215) 652-0994. E-mail: david_kaslow{at}merck.com.

Infection and Immunity, March 2000, p. 1418-1427, Vol. 68, No. 3
0019-9567/00/$04.00+0


This article has been cited by other articles:

  • Wipasa, J., Xu, H., Liu, X., Hirunpetcharat, C., Stowers, A., Good, M. F. (2009). Effect of Plasmodium yoelii Exposure on Vaccination with the 19-Kilodalton Carboxyl Terminus of Merozoite Surface Protein 1 and Vice Versa and Implications for the Application of a Human Malaria Vaccine. Infect. Immun. 77: 817-824 [Abstract] [Full Text]  
  • Carralot, J.-P., Lemmel, C., Stevanovic, S., Pascolo, S. (2008). Mass spectrometric identification of an HLA-A*0201 epitope from Plasmodium falciparum MSP-1. Int Immunol 20: 1451-1456 [Abstract] [Full Text]  
  • Huaman, M. C., Martin, L. B., Malkin, E., Narum, D. L., Miller, L. H., Mahanty, S., Long, C. A. (2008). Ex Vivo Cytokine and Memory T Cell Responses to the 42-kDa Fragment of Plasmodium falciparum Merozoite Surface Protein-1 in Vaccinated Volunteers. J. Immunol. 180: 1451-1461 [Abstract] [Full Text]  
  • Faber, B. W., Remarque, E. J., Morgan, W. D., Kocken, C. H. M., Holder, A. A., Thomas, A. W. (2007). Malaria Vaccine-Related Benefits of a Single Protein Comprising Plasmodium falciparum Apical Membrane Antigen 1 Domains I and II Fused to a Modified Form of the 19-Kilodalton C-Terminal Fragment of Merozoite Surface Protein 1. Infect. Immun. 75: 5947-5955 [Abstract] [Full Text]  
  • Woehlbier, U., Epp, C., Kauth, C. W., Lutz, R., Long, C. A., Coulibaly, B., Kouyate, B., Arevalo-Herrera, M., Herrera, S., Bujard, H. (2006). Analysis of Antibodies Directed against Merozoite Surface Protein 1 of the Human Malaria Parasite Plasmodium falciparum. Infect. Immun. 74: 1313-1322 [Abstract] [Full Text]  
  • VALDERRAMA-AGUIRRE, A., QUINTERO, G., GOMEZ, A., CASTELLANOS, A., PEREZ, Y., MENDEZ, F., AREVALO-HERRERA, M., HERRERA, S. (2005). ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. Am J Trop Med Hyg 73: 16-24 [Abstract] [Full Text]  
  • John, C. C., O'Donnell, R. A., Sumba, P. O., Moormann, A. M., de Koning-Ward, T. F., King, C. L., Kazura, J. W., Crabb, B. S. (2004). Evidence That Invasion-Inhibitory Antibodies Specific for the 19-kDa Fragment of Merozoite Surface Protein-1 (MSP-119) Can Play a Protective Role against Blood-Stage Plasmodium falciparum Infection in Individuals in a Malaria Endemic Area of Africa. J. Immunol. 173: 666-672 [Abstract] [Full Text]  
  • Okech, B. A., Corran, P. H., Todd, J., Joynson-Hicks, A., Uthaipibull, C., Egwang, T. G., Holder, A. A., Riley, E. M. (2004). Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia. Infect. Immun. 72: 1557-1567 [Abstract] [Full Text]  
  • Stowers, A. W., Kennedy, M. C., Keegan, B. P., Saul, A., Long, C. A., Miller, L. H. (2002). Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria. Infect. Immun. 70: 6961-6967 [Abstract] [Full Text]  
  • Egan, A. F., Fabucci, M. E., Saul, A., Kaslow, D. C., Miller, L. H. (2002). Aotus New World monkeys: model for studying malaria-induced anemia. Blood 99: 3863-3866 [Abstract] [Full Text]  
  • Ahlborg, N., Ling, I. T., Howard, W., Holder, A. A., Riley, E. M. (2002). Protective Immune Responses to the 42-Kilodalton (kDa) Region of Plasmodium yoelii Merozoite Surface Protein 1 Are Induced by the C-Terminal 19-kDa Region but Not by the Adjacent 33-kDa Region. Infect. Immun. 70: 820-825 [Abstract] [Full Text]  
  • King, C. L., Malhotra, I., Wamachi, A., Kioko, J., Mungai, P., Wahab, S. A., Koech, D., Zimmerman, P., Ouma, J., Kazura, J. W. (2002). Acquired Immune Responses to Plasmodium falciparum Merozoite Surface Protein-1 in the Human Fetus. J. Immunol. 168: 356-364 [Abstract] [Full Text]  
  • O'Donnell, R. A., de Koning-Ward, T. F., Burt, R. A., Bockarie, M., Reeder, J. C., Cowman, A. F., Crabb, B. S. (2001). Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria. JEM 193: 1403-1412 [Abstract] [Full Text]  
  • Stowers, A. W., Cioce, V., Shimp, R. L., Lawson, M., Hui, G., Muratova, O., Kaslow, D. C., Robinson, R., Long, C. A., Miller, L. H. (2001). Efficacy of Two Alternate Vaccines Based on Plasmodium falciparum Merozoite Surface Protein 1 in an Aotus Challenge Trial. Infect. Immun. 69: 1536-1546 [Abstract] [Full Text]  
  • Kumar, S., Collins, W., Egan, A., Yadava, A., Garraud, O., Blackman, M. J., Patino, J. A. G., Diggs, C., Kaslow, D. C. (2000). Immunogenicity and Efficacy in Aotus Monkeys of Four Recombinant Plasmodium falciparum Vaccines in Multiple Adjuvant Formulations Based on the 19-Kilodalton C Terminus of Merozoite Surface Protein 1. Infect. Immun. 68: 2215-2223 [Abstract] [Full Text]  
  • Stowers, A. W., Chen, L.-h., Zhang, Y., Kennedy, M. C., Zou, L., Lambert, L., Rice, T. J., Kaslow, D. C., Saul, A., Long, C. A., Meade, H., Miller, L. H. (2002). A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 99: 339-344 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»